I-Mab Current Ratio 2020-2021 | IMAB

I-Mab current ratio from 2020 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
I-Mab Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.81B $0.09B 9.47
2020-12-31 $0.82B $0.09B 9.28
2020-09-30 $0.47B $0.05B 9.18
2019-12-31 $0.20B $0.05B 4.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.887B $0.236B
I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86